Skip to content

Corcept Therapeutics

US · CORT #1285 by market cap Listed 1970
119.60 +0.03 +0.03%
Live - 5344 symbols - heartbeat 102s ago · 2026-10-08 06:36
Pre-market 120.67 +0.89%
After-hours 119.60 0.00%
Market cap
12.93B
P/B
18.32
EPS
0.82
Reader sentiment Are you bullish or bearish on CORT?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Form 144 | Corcept Therapeutics(CORT.US) Director Proposes to Sell 3.34 Million in Common Stocks
    Market Newswire · 2026/9/15
  • Rating change
    Truist Financial Initiates Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $164
    Market Newswire · 2026/8/18
  • Rating change
    Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $88
    Market Newswire · 2026/6/1
  • Rating change
    CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/5/4
  • Rating change
    H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $95
    Market Newswire · 2026/6/2
  • Rating change
    H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $165
    Market Newswire · 2026/7/30
  • H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
    Market Newswire · 2026/9/19
  • Rating change
    CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $135
    Market Newswire · 2026/5/28
  • Rating change
    H.C. Wainwright Keeps Their Buy Rating on Corcept Therapeutics (CORT)
    TipRanks · 2026/6/1
  • Corcept Therapeutics(CORT.US) Officer Sells US$3.89 Million in Common Stock
    Market Newswire · 2026/8/28
  • Rating change
    UBS Upgrades Corcept Therapeutics(CORT.US) to Buy Rating, Cuts Target Price to $72
    Market Newswire · 2026/5/13
  • Rating change
    CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $161
    Market Newswire · 2026/7/29
  • Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $165
    Market Newswire · 2026/8/21
  • Corcept Therapeutics(CORT.US) Director Sells US$12.25 Million in Common Stock
    Market Newswire · 2026/8/21
  • Rating change
    CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $161
    Market Newswire · 2026/8/13
  • Rating change
    CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135
    Market Newswire · 2026/7/9
  • Rating change
    H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $95
    Market Newswire · 2026/5/28
  • Rating change
    Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $165
    Market Newswire · 2026/7/30
  • Rating change
    Wolfe Research Downgrades Corcept Therapeutics(CORT.US) to Sell Rating, Announces Target Price $50
    Market Newswire · 2026/7/27
  • Rating change
    Wolfe Research Maintains Corcept Therapeutics(CORT.US) With Sell Rating, Maintains Target Price $50
    Market Newswire · 2026/7/30

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 06:36:38 · For reference only, not investment advice and not tailored to your situation.